Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior split

Data ReadoutpositiveCarvyktiPositive

AI Analysis

Summary

Legend Biotech reported five-year data for Carvykti in relapsed/refractory multiple myeloma, with 10 of 20 patients showing sustained response, supporting arguments for potential curative benefit. The article also mentions news regarding Addex, Indivior, Amberstone, Henlius, and Boehringer Ingelheim.

Clinical Trial Data

Primary Endpoint

Met

Patients

Outcome Details

Five-year data from relapsed/refractory multiple myeloma patients showed 10 of 20 patients with sustained response, suggesting potential curative benefit

Importance:7/10

Sentiment:

0.75

CAR-Toncologymultiple myelomalong-term datacure potential

Related Companies

$LEGN $ADXN $INDV.L

Read the original article

Published by Endpoints News on September 25, 2026 2:34 PM

Read Original